These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19895166)

  • 1. Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma.
    Minarik J; Scudla V; Bacovsky J; Zemanova M; Pika T; Ordeltova M; Langova K
    Neoplasma; 2010; 57(1):8-14. PubMed ID: 19895166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
    Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
    Minarik J; Scudla V; Ordeltova M; Bacovsky J; Pika T; Langova K
    Eur J Haematol; 2009 Dec; 83(6):528-34. PubMed ID: 19624720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
    Satoh M; Oguro R; Yamanaka C; Takada K; Matsuura Y; Akiba T; Aotsuka N; Tani Y; Wakita H
    J Pharm Pharm Sci; 2011; 14(1):78-89. PubMed ID: 21501555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and the current trends in multiple myeloma therapy.
    Dmoszyńska A
    Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients.
    Chim CS
    J Transl Med; 2010 Nov; 8():124. PubMed ID: 21108845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic significance of morphology in multiple myeloma].
    Al-Sahmani M; Trnavská I; Antošová M; Antošová L; Kissová J; Kaisarová B; Adam Z; Buliková A; Penka M; Hájek R
    Klin Onkol; 2012; 25(2):103-9. PubMed ID: 22533884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
    Badros A; Gahres N
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432
    [No Abstract]   [Full Text] [Related]  

  • 10. Lenalidomide efficacy in bortezomib-resistant myeloma.
    Gozzetti A; Crupi R; Defina M; Bocchia M
    Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824907
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel agents for multiple myeloma treatment.
    Ribatti D; Vacca A
    Curr Pharm Biotechnol; 2006 Dec; 7(6):395. PubMed ID: 17168654
    [No Abstract]   [Full Text] [Related]  

  • 12. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
    Krejci M; Gregora E; Straub J; Minarik J; Scudla V; Adam Z; Krivanova A; Pour L; Zahradova L; Buchler T; Mayer J; Hajek R
    Ann Hematol; 2011 Dec; 90(12):1441-7. PubMed ID: 21380511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.
    Prince HM; Schenkel B; Mileshkin L
    Leukemia; 2007 Apr; 21(4):818-20; author reply 821. PubMed ID: 17301817
    [No Abstract]   [Full Text] [Related]  

  • 15. [Current therapy for multiple myeloma].
    Swieboda-Sadlej A
    Pol Arch Med Wewn; 2005 Oct; 114(4):1030-6. PubMed ID: 16789532
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
    del Giglio A; Weinschenker P; Manhani AR; Carbonell AL; Mitteldorf CA
    South Med J; 2005 Feb; 98(2):238-40. PubMed ID: 15759959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatments in multiple myeloma: beyond optimal treatment.
    Harousseau JL
    Ann Oncol; 2008 Jul; 19 Suppl 5():v68-70. PubMed ID: 18611904
    [No Abstract]   [Full Text] [Related]  

  • 18. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance treatment in multiple myeloma.
    Harousseau JL
    Ann Oncol; 2008 Jun; 19 Suppl 4():iv54-5. PubMed ID: 18519405
    [No Abstract]   [Full Text] [Related]  

  • 20. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.